On Monday, Neumora Therapeutics Inc (NASDAQ: NMRA) opened lower -5.32% from the last session, before settling in for the closing price of $1.88. Price fluctuations for NMRA have ranged from $1.81 to $21.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 55.94% at the time writing. With a float of $55.17 million, this company’s outstanding shares have now reached $160.48 million.
In an organization with 124 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Neumora Therapeutics Inc (NMRA) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Neumora Therapeutics Inc is 65.85%, while institutional ownership is 30.15%. The most recent insider transaction that took place on Oct 18 ’24, was worth 239,319. In this transaction Director of this company sold 14,049 shares at a rate of $17.03, taking the stock ownership to the 20,100 shares. Before that another transaction happened on Oct 17 ’24, when Company’s Director sold 7,739 for $17.01, making the entire transaction worth $131,643. This insider now owns 20,100 shares in total.
Neumora Therapeutics Inc (NMRA) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 55.94% per share during the next fiscal year.
Neumora Therapeutics Inc (NASDAQ: NMRA) Trading Performance Indicators
Check out the current performance indicators for Neumora Therapeutics Inc (NMRA). In the past quarter, the stock posted a quick ratio of 10.98.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.85, a number that is poised to hit -0.44 in the next quarter and is forecasted to reach -1.61 in one year’s time.
Technical Analysis of Neumora Therapeutics Inc (NMRA)
Let’s dig in a bit further. During the last 5-days, its volume was 1.64 million. That was inferior than the volume of 5.88 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 29.86%. Additionally, its Average True Range was 0.35.
During the past 100 days, Neumora Therapeutics Inc’s (NMRA) raw stochastic average was set at 0.45%, which indicates a significant decrease from 14.89% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 46.25% in the past 14 days, which was lower than the 276.10% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.0923, while its 200-day Moving Average is $10.0261. However, in the short run, Neumora Therapeutics Inc’s stock first resistance to watch stands at $1.8633. Second resistance stands at $1.9467. The third major resistance level sits at $2.0233. If the price goes on to break the first support level at $1.7033, it is likely to go to the next support level at $1.6267. Assuming the price breaks the second support level, the third support level stands at $1.5433.
Neumora Therapeutics Inc (NASDAQ: NMRA) Key Stats
There are currently 161,561K shares outstanding in the company with a market cap of 287.57 million. Presently, the company’s annual sales total 0 K according to its annual income of -235,930 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -72,550 K.
